July 9, 2026

A Rival’s Failure Just Handed Alnylam a $15B Market

Featured: A Rival’s Failure Just Handed Alnylam a $15B Market

Sponsored

Big Pharma’s $560B White Flag is One Startup’s Ticket

Big Pharma spent decades and $1B trying to solve osteoarthritis. They kept failing because they only targeted one of the many culprits attacking joints. Cytonics figured that out.

They created the first therapy with the potential to address the root cause at the molecular level, already proven across 10,000+ patients. Now they’re pushing toward FDA approval on a version that’s 200% more potent, backed by $32M raised and partnerships with Stanford and Scripps Research.

Invest in Cytonics before this month’s deadline.

This is a paid advertisement for Cytonics Regulation CF offering. Please read the offering circular at https://cytonics.com/
Forward-looking statements are subject to risks and uncertainties. There is no guarantee of performance. Past performance does not predict future results. All investments involve risk, including loss of principal.

What’s interesting is how cleanly the market read the second-order trade. Alnylam’s AMVUTTRA (vutrisiran) already leads the ATTR-CM market. Today’s competitor failure did not just remove near-term pricing pressure. It eliminated what Wall Street had treated as the most credible threat to Alnylam’s franchise dominance.

The numbers make the competitive context clear. In Q1 2026, Alnylam’s TTR franchise grew 153% year over year to $910 million — AMVUTTRA alone contributed $890 million of that — with total product revenue crossing $1 billion in a single quarter for the first time in company history. Full-year 2026 guidance calls for combined net product revenue of $4.9 billion to $5.3 billion, representing roughly 71% growth at the midpoint.

This is also a story about the difficulty of challenging an RNAi mechanism in a disease space that has already been reshaped by gene-silencing biology. The CARDIO-TTRansform failure was not random. Exactly 57% of enrolled patients were already receiving TTR stabilizer therapy at baseline, and adding eplontersen on top provided no statistically significant additional benefit. That result does not just close the Wainua chapter. It reinforces why Alnylam’s platform-level approach is harder to displace than a single-molecule competitor.

Stifel maintained its Buy rating immediately following the news, noting that the trial result removes a key valuation overhang from the competitive landscape. BridgeBio Pharma, another ATTR-CM player, also surged — climbing 14% in the premarket session — as investors rotated toward companies that benefit from Wainua’s exit. The market moved fast to reprice who controls this space for the next several years.

Here’s where it gets more interesting. Even with today’s surge, Alnylam shares had been down roughly 24% year to date through the end of June. The stock still trades well below its 52-week high of $495.55. The analyst consensus price target sits around $457 to $461 — meaningful upside from levels even after the morning spike.

The pipeline is not standing still either. Nucresiran, the next-generation RNAi therapeutic targeting ATTR amyloidosis, is in Phase 3 development — and enrollment in the TRITON-CM study is actually ahead of pace, with the company expanding target enrollment from 1,250 to approximately 1,750 patients to capture more events. Zilebesiran is in late-stage trials for hypertension. An early-stage obesity program just initiated a Phase 1 study. This is a company transitioning from rare disease specialist into what looks increasingly like a broad-based internal medicine platform.

What Investors Are Watching

The remaining competitive threats in ATTR-CM are fewer but real. Pfizer’s tafamidis and BridgeBio’s acoramidis remain commercial alternatives in the stabilizer class. But neither operates via RNAi, and today’s data reinforces that adding a second mechanism on top of established TTR stabilization does not translate into clinical benefit in a meaningful portion of the patient population.

That distinction matters. Alnylam’s mechanism works differently and the clinical data continues to hold up in conditions where competitor approaches have struggled.

The Q2 2026 earnings call is scheduled for July 30. Management will need to show that AMVUTTRA prescription momentum is sustainable and that the international rollout is tracking toward the full-year revenue target. If those numbers hold, today’s competitive windfall starts looking less like a one-day event and more like a revaluation moment the market had been deferring. The full CARDIO-TTRansform data set is expected to be presented at the European Society of Cardiology Congress in August — that disclosure could add further clarity on exactly how large Alnylam’s competitive gap has become.

The question worth sitting with is not whether today’s move was justified. It clearly was. The real question is whether the market has now fully priced what it means to be the last credible RNAi platform standing in one of cardiology’s fastest-growing rare disease categories — or whether this is still the beginning of that shift.